Læknablaðið - 15.11.1988, Page 12

358
LÆKNABLAÐIÐ
9. Burstein M, Scholnick HR, Morfin R. Rapid
estimation for the isolation of lipoproteins from
human serum by preciptitation with polyanions. J
Lipid Res 1970; 11: 583-95.
10. Friedewald WT, Levy RI, Frederickson DS.
Estimation of the concentration of low-density
lipoprotein cholesterol in plasma without use of the
preparative ultracentrifuge. Clin Chem 1972; 18:
499-502.
11. Illingworth DR. Specific inhibitors of cholesterol
biosynthesis and hypocholesterolemic agents in
humans: Mevinolin and compactin.
Pharmacological control of Hyperlipidemia. Prous
Science Publishers SA 1986: 231-49.
12. Illingworth DR, Sexton GJ. Hypocholesterolemic
effects of mevinolin in patients with heterozygon
familial hyopercolesterolemia. J Clin Invest 1984;
74: 1972-8.
13. Havel RJ et al. Lovastatin (Mevinolin) in the
treatment of heterozygons familial
hypercholesterolemia. A multicenter study. Ann Int
Med 1978; 107: 609-15.
14. NIH consensus development conference statement,
lowering blood cholesterol to prevent heart disease.
Arteriosclerosis 1985; 5 : 404-12.
15. Illingworth RD. Comparative efficiency of once
versus twice daily mevinolin in the therapy of
familial hypercholesterolemia. Clin Parmacol Ther
1986; 40: 338-43.
16. Lipid Research Clinics Program. The lipid research
clinics coronary primary prevention trial results: 1.
reduction in incidence of coronary heart disease.
JAMA 1984; 251: 351-64.
17. Sigurdsson G. Arfgeng hyperkólesterolemía.
Læknablaðið 1980; 66: 103-9.
18. Vega GL, Grundy SM. Treatment of primary
moderate hypercholesterolemia with lovastatin
(mevinolin) and colestipol. JAMA 1987; 257: 33-8.
19. Bilheimer DW, Grundy SM, Brown MS, Goldstein
JL. Mevinolin and colestipol stimulate receptor -
medicated clearance of low density lipoprotein
from plasma in familial hypercholesterolemia
heterozygotes. Proc Natl Acad Sci-USA 1983; 80:
4124-8.
20. Frick MH et al. Helsinki heart study: Primary
prevention trial with gemfibrosil in middle-aged
men with dyslipidemia. N Engl J Med 1987; 317:
1237-45.
21. Hunninghake DB, Miller VT, Palmer RH.
Therapeutic response to lovastatin in nonfamilial
hypercholesterolemia. JAMA 1986; 256: 2829-34.
22. Castelli WP, Garrison RJ, Wilson PWP, Abbott
DR, Kaloushin R, Kannel WB. Incidence of
‘ coronary heart disease and lipoprotein cholesterol
levels. The Framingham study. JAMA 1986; 256:
2835-8.
23. Hveg JM, Maher MB, Bailey KR et al. Comparison
of six pharmacological regimens for
hypercholesterolemia. Am J Cardiol 1987; 59:
812-15.
24. Hoeg JM, Brewer HB.
3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitors in the treatment of hypercholesterolemia.
JAMA 1987; 258: 3532-6.
25. Illingworth DR, Corbin D. The influecne of
mevinolin on the adrenal cortical response to
corticotropin in heterozygous familial
hypercholesterolemia. Proc Natl Acad Sci USA
1985; 82: 6291-4.
26. Blankenhorn DH et al. Benefical effects of
combined colestipol-niacin therapy on coronary
atherosclerosis and coronary venous bypass grafts.
JAMA 1987; 257: 3233-40.